24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Insulin Doesn't Prevent Diabetes in Relatives of T1DM PatientsInsulin Pill May Delay Type 1 Diabetes in SomeHealth Tip: Diabetes Affects Women DifferentlySevere Psoriasis May Make Diabetes Increasingly LikelySpinal Cord Stimulation May Reduce Neuropathic PainBrain Glucose Responses Diminish With Diabetes, ObesityRisk of Falls Up With Mild, Moderate Diabetic RetinopathyFirst-Line Metformin Use for DM Up; Sulfonylurea Use DownPoor Prognosis for Diabetic Foot SoresER- Breast CA Risk Up for African-Americans With T2DMIn 2007-2014, Glycemic Control Plateaued in Diabetes PatientsDiabetes May Be Driving High Rates of Breast Cancer in Black WomenLeisure Time Exercise Linked to Reduced Mortality in T1DMAHA: Sudden Cardiac Death Risk Up for Young With DiabetesYounger People With Diabetes Have 7 Times Greater Risk of Sudden Heart DeathRisk of End-Stage Renal Disease Low With Type 1 DiabetesDrop in Incidence of End-Stage Renal Disease Due to DiabetesHealth Tip: Choosing Smarter FoodsLifestyle Changes Successfully Reduce Incidence of DiabetesNovel Method Developed for Estimating Prevalence of DiabetesNovel Artificial Pancreas Cuts HbA1c, Hypoglycemia in T1DMKidney Failure Declining Among U.S. Diabetics: CDCACE Inhibitor, Statin No Benefit for T1DM, High Albumin ExcretionMagnesium, T2DM Link Seen in Poor-Carbohydrate-Quality DietRetinal Sensitivity Linked to Cognitive Status in T2DMKidney Damage Seen in Most Patients With Long-Lasting T1DArterial Stiffness Linked to Incidence of DiabetesUndiagnosed Diabetes Accounts for Small Portion of DiabetesNew Clinical Practice Guideline for Management of T2DMDiabetes Tied to Worse Outcomes in Heart Failure PatientsStatins May Raise Odds of T2DM in Those at High RiskFinancial Incentives Up Teen Glucose Monitoring AdherenceFewer Diabetes Cases Being MissedSudden Death Most Common CV Death in T2DM/ASCVDDiabetes Ups Risk of MACE in Acute Coronary SyndromesLifestyle, Metformin Interventions Have Variable EffectsHealth Tip: Best Grains And Starchy Veggies for DiabeticsGlycemic Control Up With Oral Semaglutide in Type 2 DiabetesCommercial Weight Management Program May Help Prevent T2DDiabetes Pill Might Replace Injection to Control Blood SugarNew Screening Tool Can Identify Diabetic RetinopathyRisk Conferred by T2D Modified by HbA1c in Heart FailureNo Causal Link Between Plasma Lipids, Diabetic RetinopathyBetter Glycemic Control With Insulin Pump for Youth With T1DPump May Beat Shots for Type 1 DiabetesWhere There's Type 1 Diabetes, Celiac Disease May FollowFlu Shot Key for People With DiabetesMaking Halloween a Treat for Kids With DiabetesPay for Performance Cuts Mortality in Diabetes PatientsAddition of DPP4i to AGI Reduces HbA1c in T2DM
Links
Related Topics

Medical Disorders

What Drugs Work Best for Diabetic Nerve Pain?

HealthDay News
by -- Robert Preidt
Updated: Mar 24th 2017

new article illustration

FRIDAY, March 24, 2017 (HealthDay News) -- Nerve pain and numbness, also known as neuropathy, is a debilitating but common symptom of diabetes.

Now, new research suggests certain drugs may outperform others in treating diabetic neuropathy.

The new review of the data on the subject was led by Julie Waldfogel of Johns Hopkins Hospital in Baltimore. Her team noted that about half of people with diabetes have some form of nerve damage caused by high levels of blood sugar.

However, not all of them will have symptoms such as pain, numbness and tingling in the legs and feet.

In the new study, the Hopkins group reviewed 106 studies on pain relief for diabetic neuropathy. The researchers found "moderate" evidence that the antidepressants duloxetine (Cymbalta) and venlafaxine (Effexor) reduce diabetic nerve pain.

However, they only found "weak" evidence that botulinum toxin (Botox), the anti-seizure drugs pregabalin (Lyrica) and oxcarbazepine (Trileptal), and drugs called tricyclic antidepressants and atypical opioids (drugs such as Tramadol) may help reduce pain.

The researchers also noted that gabapentin (Neurontin, Gralise) works in a similar manner to pregabalin, and the review found gabapentin no more effective than a placebo.

Long-term use of standard opioids -- such as OxyContin, Vicodin or Percocet -- is not recommended for chronic pain due, including neuropathy, because of a lack of evidence of long-term benefit and the risk of abuse, misuse and overdose, Waldfogel said.

The anti-seizure drug valproate and capsaicin cream were also ineffective, according to the review published online March 24 in the journal Neurology.

The review was funded by the U.S. Agency for Healthcare Research and Quality.

"Providing pain relief for neuropathy is crucial to managing this complicated disease," Waldfogel said in a journal news release.

"Unfortunately, more research is still needed, as the current treatments have substantial risk of side effects, and few studies have been done on the long-term effects of these drugs," she added.

Two experts in diabetes care and pain management said the data review is important information for patients.

"This trial was a much needed step in the right direction in an otherwise murky field of medicine," said Dr. Caroline Messer, an endocrinologist at Lenox Hill Hospital in New York City.

She noted that "traditional teaching for endocrinologists has always included the use of gabapentin for diabetic neuropathy. Given gabapentin's host of side effects, it will be a relief to remove it from the toolbox."

And Messer added that "venlafaxine is now an interesting treatment possibility, given that one of its common side effects, weight loss, could prove useful for patients with type 2 diabetes."

Dr. Ajay Misra is chair of neurosciences at Winthrop-University Hospital in Mineola, N.Y. He noted that neuropathy can differ for people with type 1 or type 2 diabetes, with neuropathy levels correlating well with blood sugar management in people with type 1 disease, but not as well for those with type 2 diabetes.

As for pain relief, Misra said "there is clearly no medication which was found to be highly effective" in the new review, so there is clearly a need for research into better analgesic options for patients.

"We hope our findings are helpful to doctors and people with diabetes who are searching for the most effective way to control pain from neuropathy," researcher Waldfogel added. "Unfortunately, there was not enough evidence available to determine if these treatments had an impact on quality of life. Future studies are needed to assess this."

More information

The American Diabetes Association has more on nerve damage from diabetes.